SCHEMBL25367694

SCHEMBL25367694

Cc1ncnc2c(C)cc(-c3sc(N)nc3-c3cccc(C#N)c3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ADORA2A P29274 7/20 0.42
MAP4K4 O95819 1/20 0.42
ADORA1 P30542 5/20 0.38
PIK3CD O00329 1/20 0.38
ABL1 P00519 1/20 0.38
EGFR P00533 1/20 0.38
HCK P08631 1/20 0.38
SRC P12931 1/20 0.38
KDR P35968 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
EPHB4 P54760 1/20 0.38
PRKDC P78527 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30520111 1.00 ALDH1A1 (0.46) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL25366229 0.85 MAP4K4 (0.56) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL30519914 0.85 MAP4K4 (0.56) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL29381457 0.79 MAPT (0.50) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL24227568 0.79 MAPT (0.50) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL25365981 0.78 MAPT (0.46) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL30520022 0.78 MAPT (0.46) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL25367687 0.77 TGFBR1 (0.47) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL30520035 0.77 TGFBR1 (0.47) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL4110516 0.77 ADORA2A (0.43) ALDH1A1MAPTLMNAMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243194-A1 ANTAGONIST OF ADENOSINE RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2025-07-31 US disclosed
WO-2023144559-A1 ANTAGONIST OF ADENOSINE RECEPTORS AdoRx Therapeutics Limited (GB) 2023-08-03 WO disclosed
WO-2023144559-A1 ANTAGONIST OF ADENOSINE RECEPTORS AdoRx Therapeutics Limited (GB) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243194-A1 ANTAGONIST OF ADENOSINE RECEPTORS ADORA2B, ADORA2A, ADORA1 ALDH1A1 637/4885MAPT 4767/4885LMNA 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.